145 related articles for article (PubMed ID: 25461250)
21. Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells.
Sarkar M; Han T; Damaraju V; Carpenter P; Cass CE; Agarwal RP
Biochem Pharmacol; 2005 Aug; 70(3):426-32. PubMed ID: 15950950
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients.
Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2014 Jan; 199(1):103-9. PubMed ID: 24332606
[TBL] [Abstract][Full Text] [Related]
23. Activation of deoxycytidine kinase by various nucleoside analogues.
Spasokoukotskaja T; Sasvári-Székely M; Hullán L; Albertioni F; Eriksson S; Staub M
Adv Exp Med Biol; 1998; 431():641-5. PubMed ID: 9598144
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of anti-cancer action and pharmacology of clofarabine.
Zhenchuk A; Lotfi K; Juliusson G; Albertioni F
Biochem Pharmacol; 2009 Dec; 78(11):1351-9. PubMed ID: 19576186
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
26. Resistance to 2-chloro-2'-deoxyadenosine of the human B-cell leukemia cell line EHEB.
Cardoen S; Van Den Neste E; Smal C; Rosier JF; Delacauw A; Ferrant A; Van den Berghe G; Bontemps F
Clin Cancer Res; 2001 Nov; 7(11):3559-66. PubMed ID: 11705877
[TBL] [Abstract][Full Text] [Related]
27. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.
Kim W; Le TM; Wei L; Poddar S; Bazzy J; Wang X; Uong NT; Abt ER; Capri JR; Austin WR; Van Valkenburgh JS; Steele D; Gipson RM; Slavik R; Cabebe AE; Taechariyakul T; Yaghoubi SS; Lee JT; Sadeghi S; Lavie A; Faull KF; Witte ON; Donahue TR; Phelps ME; Herschman HR; Herrmann K; Czernin J; Radu CG
Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4027-32. PubMed ID: 27035974
[TBL] [Abstract][Full Text] [Related]
28. Clofarabine: a new treatment option for patients with acute myeloid leukemia.
Larson ML; Venugopal P
Expert Opin Pharmacother; 2009 Jun; 10(8):1353-7. PubMed ID: 19463072
[TBL] [Abstract][Full Text] [Related]
29. Clofarabine in leukemia.
Ghanem H; Jabbour E; Faderl S; Ghandhi V; Plunkett W; Kantarjian H
Expert Rev Hematol; 2010 Feb; 3(1):15-22. PubMed ID: 21082931
[TBL] [Abstract][Full Text] [Related]
30. Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5'-nucleotidase mRNA measurement in cell lines and in patients with leukemia.
Månsson E; Liliemark E; Söderhäll S; Gustafsson G; Eriksson S; Albertioni F
Leukemia; 2002 Mar; 16(3):386-92. PubMed ID: 11896543
[TBL] [Abstract][Full Text] [Related]
31. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
[TBL] [Abstract][Full Text] [Related]
32. Potential of ribozymes against deoxycytidine kinase to confer drug resistance to cytosine nucleoside analogs.
Beauséjour CM; Tremblay G; Momparler RL
Biochem Biophys Res Commun; 2000 Nov; 278(3):569-75. PubMed ID: 11095951
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.
Parker WB; Shaddix SC; Gilbert KS; Shepherd RV; Waud WR
Cancer Chemother Pharmacol; 2009 Jul; 64(2):253-61. PubMed ID: 19002461
[TBL] [Abstract][Full Text] [Related]
34. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.
Veuger MJ; Honders MW; Willemze R; Barge RM
Eur J Haematol; 2002 Sep; 69(3):171-8. PubMed ID: 12406011
[TBL] [Abstract][Full Text] [Related]
35. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
Hapke DM; Stegmann AP; Mitchell BS
Cancer Res; 1996 May; 56(10):2343-7. PubMed ID: 8625309
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity.
Freiburghaus C; Emruli VK; Johansson A; Eskelund CW; Grønbæk K; Olsson R; Ek F; Jerkeman M; Ek S
BMC Cancer; 2018 Apr; 18(1):466. PubMed ID: 29695239
[TBL] [Abstract][Full Text] [Related]
37. Clofarabine: emerging role in leukemias.
Sampat K; Kantarjian H; Borthakur G
Expert Opin Investig Drugs; 2009 Oct; 18(10):1559-64. PubMed ID: 19715446
[TBL] [Abstract][Full Text] [Related]
38. Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.
Wu B; Mao ZJ; Wang Z; Wu P; Huang H; Zhao W; Zhang L; Zhang Z; Yin H; Gale RP; Yin B
Acta Haematol; 2021; 144(5):534-541. PubMed ID: 33626530
[TBL] [Abstract][Full Text] [Related]
39. Clofarabine for the treatment of acute lymphoblastic leukemia.
Jeha S; Kantarjian H
Expert Rev Anticancer Ther; 2007 Feb; 7(2):113-8. PubMed ID: 17288522
[TBL] [Abstract][Full Text] [Related]
40. Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine.
Jeha S
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1137-44, viii. PubMed ID: 19825457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
